XTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

XTX Topco Ltd acquired a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 67,201 shares of the company's stock, valued at approximately $277,000. XTX Topco Ltd owned approximately 0.09% of Trevi Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Summit Investment Advisors Inc. lifted its stake in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Trevi Therapeutics by 2.1% during the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock worth $578,000 after buying an additional 2,935 shares during the period. SG Americas Securities LLC boosted its stake in Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock valued at $110,000 after buying an additional 3,387 shares in the last quarter. Invesco Ltd. grew its position in Trevi Therapeutics by 21.2% in the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after acquiring an additional 4,133 shares during the period. Finally, Wells Fargo & Company MN raised its stake in Trevi Therapeutics by 40.7% during the fourth quarter. Wells Fargo & Company MN now owns 33,050 shares of the company's stock worth $136,000 after acquiring an additional 9,562 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TRVI has been the topic of several analyst reports. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. B. Riley reaffirmed a "buy" rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Oppenheimer lifted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $12.50 price target on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $17.56.

Trevi Therapeutics Stock Performance

NASDAQ TRVI opened at $6.47 on Friday. Trevi Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.39. The stock has a market capitalization of $625.53 million, a P/E ratio of -14.70 and a beta of 0.41. The stock has a fifty day moving average of $5.71 and a 200-day moving average of $4.27.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. Equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Activity at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $1,403,599.54. This represents a 2.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is currently owned by company insiders.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.